A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis - Wikidata - wikimedia - TriplyDB

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

http://www.wikidata.org/entity/Q28270998

about

Sphingolipids: a potential molecular approach to treat allergic inflammation Neurodegeneration in multiple sclerosis: novel treatment strategies New and emerging disease modifying therapies for multiple sclerosis N-Acetylglucosamine Inhibits T-helper 1 (Th1)/T-helper 17 (Th17) Cell Responses and Treats Experimental Autoimmune Encephalomyelitis Current Concepts in Multiple Sclerosis: Autoimmunity Versus Oligodendrogliopathy Cost-Effectiveness of Disease-Modifying Therapies in Multiple Sclerosis Multiple Sclerosis: Where Will We Be in 2020?Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, Fingolimod will change therapeutic paradigm approach Fingolimod for relapsing-remitting multiple sclerosis Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis Intravenous immunoglobulin to prevent relapses during pregnancy and postpartum in multiple sclerosis Pharmacological treatment for memory disorder in multiple sclerosis Fingolimod for relapsing remitting multiple sclerosis Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine Actions of a picomolar short-acting S1P₁ agonist in S1P₁-eGFP knock-in mice Depressogenic effects of medications: a review Impact of Exercise on Innate Immunity in Multiple Sclerosis Progression and Symptomatology The emerging role of FTY720 (Fingolimod) in cancer treatment Fingolimod in the treatment of relapsing-remitting multiple sclerosis: long-term experience and an update on the clinical evidence Dimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerations The challenge of comorbidity in clinical trials for multiple sclerosis Fingolimod for multiple sclerosis and emerging indications: appropriate patient selection, safety precautions, and special considerations B Cells Are Multifunctional Players in Multiple Sclerosis Pathogenesis: Insights from Therapeutic Interventions Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis Ponesimod, a selective S1P1 receptor modulator: a potential treatment for multiple sclerosis and other immune-mediated diseases Optimizing treatment success in multiple sclerosis Fingolimod Real World Experience: Efficacy and Safety in Clinical Practice The Effect of Disease Modifying Therapies on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis Importance of Apolipoprotein A-I in Multiple Sclerosis Future perspectives in target-specific immunotherapies of myasthenia gravis Disease-modifying treatments for multiple sclerosis - a review of approved medications Optimizing the initial choice and timing of therapy in relapsing-remitting multiple sclerosis Newer therapies for multiple sclerosis Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group Migration and pathogenicity of CD8 T cells in central nervous system diseases Novel Insights and Therapeutics in Multiple Sclerosis Treatment strategies for multiple sclerosis: When to start, when to change, when to stop?Sphingosine 1-phosphate receptor modulators in multiple sclerosis Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond

P2860

Q21296721-28CAAF6F-E3ED-48BC-91DE-DFD9D011AB6D Q22241472-E10488E6-8C12-4254-A32D-36051A29AD28 Q22242305-757B609E-42EC-4D53-8DC0-1E650D501AB4 Q22248070-5F663CF9-86CB-4D2A-9564-0E807C7D105D Q22252578-A3593E53-85C8-4C9C-B792-D1B04CFE263F Q22252598-6F99740C-5BD2-4E80-8FDA-A7D8486B8586 Q22252863-4517BD3E-3369-4FD3-8AE8-4DBAE8EC8E40 Q22305854-5C21BCF8-732F-4088-A298-4710D58BF117 Q24185882-17428F87-0644-4640-AD1F-B0BAD2017706 Q24187126-D9E3146D-F090-4A1C-9C92-E85C38203A97 Q24201599-FAF1BBE1-8332-4EAF-A740-B9B674014861 Q24201735-F9311A7A-759E-4D31-A04D-32042B1B7BA4 Q24236597-A404D72F-8DD7-4C19-B903-4037717826ED Q24564715-DBA2A69A-9B2B-4AA0-BEA5-D169DFC42F78 Q24597369-8AE849D4-29EB-41D7-BA28-B1E412F4A7DA Q24609856-C68BB88B-958A-4E88-9B66-C0F21C4206CA Q24635465-946986BD-796A-4DB3-BFF3-0EC6C06883CE Q26745562-90B45A9B-EB0A-47B6-B675-33CAFEFE1310 Q26748927-6F338BC9-325D-4763-8D98-39FF5C6268EE Q26752466-5B3194F0-D3FA-4D96-A813-5281D5003F16 Q26752859-F81DFFA8-0C60-426E-993D-41431D79A1AA Q26765031-1C925B7D-4F78-43A7-97F4-7836669DE856 Q26765300-3CF63D37-8B35-4F54-AF73-8FA21770A81A Q26770664-B9D671B4-F048-4ED5-9F47-85D0234E8787 Q26771635-62C37A7A-B85E-4D03-80E1-897F26F63DA7 Q26771821-137DAB98-FFBF-40A1-8100-91C5E54DC6D0 Q26771968-4027A9BB-7429-4A86-B1F8-F1854DCA10B3 Q26773532-23A3D2AE-47B2-4C0F-A65D-84B956AE23D9 Q26773978-7D3EE67A-CCD3-4B78-9403-DDFC19194DE4 Q26774792-4D46873F-B6A5-477D-8C57-E49D19621794 Q26776225-B6E83C3E-88B0-4031-B5AF-8F189398C0AC Q26777329-46BC9C0A-4DA0-4FCA-8314-A29D56350D55 Q26777686-DEA54782-909D-48DC-B60E-DEEB3B606E2C Q26779900-FA009D43-E34E-4ED5-99DA-9649C18F5511 Q26780412-56FEFB83-F265-4068-ACF5-309F858DA63F Q26784139-F7EDEC68-2274-469F-8898-D5836F5C790C Q26784619-D52F035C-B8F8-4ED6-9248-60A3C5FD4FC4 Q26798434-7B0A75A3-1527-4E17-815D-697D69FB22BC Q26799440-B734836B-F6C6-4D86-A6A5-022C72D4B4DD Q26800128-80C6CAC7-68EC-48D1-B273-BE71B090E76F

P2860

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

http://www.wikidata.org/entity/Q28270998

description

2010 nî lūn-bûn

@nan

2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

@ast

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

@en

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

@nl

type

label

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

@ast

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

@en

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

@nl

prefLabel

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

@ast

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

@en

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

@nl

P1433

Q28270998-E156E9CF-D46E-44EF-A74A-B9C471B859D1

P1476

Q28270998-8C505D35-C57E-465D-AE1F-FA960486FAC0

P2093

Q28270998-1334ED12-A403-47DD-848A-2DE4823D490B

Q28270998-4C5BA20E-C1D2-417F-8F84-E9314B928644

Q28270998-6A9CF612-3C9C-4B3B-ABA8-29400ED98D2F

Q28270998-8A99B993-BD85-4339-9EE9-FF09A83365AD

Q28270998-9CA88BAC-38CF-41F1-8771-F8AADD7A9216

Q28270998-CC9D70AB-B554-488C-A333-750E5635811D

Q28270998-EF64CA67-66BA-4A92-B516-DCCEA5868026

Q28270998-F1A70BC1-D2F1-4BE8-9217-A22D9BFAD783

Q28270998-F30BB7FB-1A14-427D-9654-548EDB222EAA

P304

Q28270998-5FCBE705-F7AD-4F67-8192-6B08A4852194

P31

Q28270998-1A2D43AF-4617-4692-83E7-FB20ADF9BC76

P3181

Q28270998-BD6021F0-52C6-4C11-AE9C-5BD745A092A9

P356

Q28270998-A65C4A8A-2C01-44F2-90B1-C568B67292BD

P407

Q28270998-DE2CEFE2-8256-4FC6-9F83-86404F22CCD4

P433

Q28270998-DEBB99D1-35D2-497A-A7A1-C893ACA49261

P478

Q28270998-E2F7DA33-82E6-4A8C-AE17-06AC51D8880F

P50

Q28270998-03FF765F-17EF-4DEC-99E5-7B3BA99E5CDA

Q28270998-2146E9FC-1139-4E06-8791-F34599F1FE9B

Q28270998-B8BBDF62-1087-4B0A-962A-CFFB1F5259FE

P577

Q28270998-3BDF3B2B-9CC0-4929-8EC2-634C7E56F5C4

P698

Q28270998-D845D3A5-BAC2-44EB-8753-F618749CC826

P921

Q28270998-327F4951-9531-4265-B86A-917D02C189C1

Q28270998-8E7668C3-D8AD-48E5-8F1D-0AE769067DB6

P3181

P356

P1433

The New England Journal of Medicine

P1476

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

@en

P2093

Catherine Agoropoulou

http://www.w3.org/2001/XMLSchema#string

Chris Polman

http://www.w3.org/2001/XMLSchema#string

Ernst-Wilhelm Radue

http://www.w3.org/2001/XMLSchema#string

Krzysztof Selmaj

http://www.w3.org/2001/XMLSchema#string

Lixin Zhang-Auberson

http://www.w3.org/2001/XMLSchema#string

Malgorzata Leyk

http://www.w3.org/2001/XMLSchema#string

Pascale Burtin

http://www.w3.org/2001/XMLSchema#string

Paul O'Connor

http://www.w3.org/2001/XMLSchema#string

Reinhard Hohlfeld

http://www.w3.org/2001/XMLSchema#string

P304

387-401

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

486744

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA0909494

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

362

http://www.w3.org/2001/XMLSchema#string

P50

Lixin Zhang-Auberson

Peter A Calabresi

P577

2010-02-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20089952

http://www.w3.org/2001/XMLSchema#string

P921

multiple sclerosis